These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29488172)

  • 1. Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.
    Srinivas NR
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):373-382. PubMed ID: 29488172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.
    Scheible H; Kraetzer F; Marx A; Johne A; Wimmer E
    Drug Metab Dispos; 2017 Feb; 45(2):174-182. PubMed ID: 27934635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
    von Richter O; Massimini G; Scheible H; Udvaros I; Johne A
    Br J Clin Pharmacol; 2016 Dec; 82(6):1498-1508. PubMed ID: 27483391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
    Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
    Arend RC; Davis AM; Chimiczewski P; O'Malley DM; Provencher D; Vergote I; Ghamande S; Birrer MJ
    Gynecol Oncol; 2020 Feb; 156(2):301-307. PubMed ID: 31870556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
    de Weger VA; de Jonge M; Langenberg MHG; Schellens JHM; Lolkema M; Varga A; Demers B; Thomas K; Hsu K; Tuffal G; Goodstal S; Macé S; Deutsch E
    Br J Cancer; 2019 Feb; 120(3):286-293. PubMed ID: 30585255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
    Delord JP; Italiano A; Awada A; Aftimos P; Houédé N; Lebbé C; Pages C; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Faivre S; Gomez-Roca C; Scheuler A; Massimini G; Raymond E
    Target Oncol; 2021 Jan; 16(1):37-46. PubMed ID: 33170484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
    Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients.
    Mahadevan D; Mita M; Richards D; McClay E; Heist RS; Kumar A; Sundararajan S; Naing A
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):681-688. PubMed ID: 28289865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
    Miller CR; Oliver KE; Farley JH
    Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
    Mita M; Fu S; Piha-Paul SA; Janku F; Mita A; Natale R; Guo W; Zhao C; Kurzrock R; Naing A
    Invest New Drugs; 2017 Oct; 35(5):616-626. PubMed ID: 28194539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
    Schram AM; Gandhi L; Mita MM; Damstrup L; Campana F; Hidalgo M; Grande E; Hyman DM; Heist RS
    Br J Cancer; 2018 Dec; 119(12):1471-1476. PubMed ID: 30425349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
    Lebbé C; Italiano A; Houédé N; Awada A; Aftimos P; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Raymond E; Faivre S; Pages C; Gomez-Roca C; Schueler A; Goodstal S; Massimini G; Delord JP
    Target Oncol; 2021 Jan; 16(1):47-57. PubMed ID: 33211315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma.
    Yamazaki K; Doi T; Ikeda M; Okusaka T; Schueler A; Watanabe M; Ohtsu A
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1027-1037. PubMed ID: 31482223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
    Facciorusso A; Licinio R; Carr BI; Di Leo A; Barone M
    Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):993-1003. PubMed ID: 25915713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical development of MEK inhibitors.
    Zhao Y; Adjei AA
    Nat Rev Clin Oncol; 2014 Jul; 11(7):385-400. PubMed ID: 24840079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.